Osivax S.A.S   Report issue

For profit Phase 1 Phase 2
Founded: Lyon France (2017)

Organization Overview

First Clinical Trial
2018
NCT03594890
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2024

Timeline

NOW
  • Now

Alternative names

Osivax | Osivax S.A.S

Active Ingredients

Drugs in Phase 2 Trials (2)

inactivated influenza vaccine (3 trials)

ovx836 (6 trials)

Drugs in Phase 1 Trials (1)

ovx033 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Influenza, Human (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 3